Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.32 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13845936 | 0.81 | CYP1A1 (0.36) | RENCYP1A1CYP1A2NFE2L2CYP1B1 | |
| SCHEMBL13845930 | 0.81 | CYP1A1 (0.36) | RENCYP1A1CYP1A2NFE2L2CYP1B1 | |
| SCHEMBL13845935 | 0.80 | CYP1A1 (0.36) | RENCYP1A1CYP1A2NFE2L2CYP1B1 | |
| SCHEMBL13636314 | 0.75 | MEN1 (0.31) | REN | |
| SCHEMBL13846057 | 0.74 | L3MBTL4 (0.43) | CYP1A1CYP1A2NFE2L2CYP1B1AR | |
| SCHEMBL13846066 | 0.73 | L3MBTL4 (0.45) | CYP1A1CYP1A2NFE2L2CYP1B1AR | |
| SCHEMBL13846061 | 0.72 | NPSR1 (0.35) | RENCYP1A1CYP1A2NFE2L2CYP1B1 | |
| SCHEMBL13845993 | 0.72 | BACE1 (0.35) | CYP1A1CYP1A2NFE2L2CYP1B1AR | |
| SCHEMBL7998889 | 0.72 | L3MBTL4 (0.38) | RENCYP1A2 | |
| SCHEMBL7989766 | 0.72 | L3MBTL4 (0.38) | RENCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009064955-A1 | MACROCYCLIC TETRAZOLYL HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |